Background
Phase III, double-blind, placebo-controlled RCT. 2840 patients with HER2+ early breast cancer who had completed ≥1 year of trastuzumab-based adjuvant therapy. Extended adjuvant neratinib (irreversible pan-HER tyrosine kinase inhibitor) vs placebo for 1 additional year. Hypothesis: residual occult disease may be eradicated by extended HER2-directed therapy post-trastuzumab.
Interventions and follow up
Arm A: Neratinib 240mg oral daily × 12 month
Arm B: Placebo × 12 month
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 8.1 years (extended analysis)
Arm B: Placebo × 12 month
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 8.1 years (extended analysis)
Results
IDFS (5-yr): 90.2% vs 87.7%, HR 0.73, 95% CI 0.57–0.92, P=.0083
IDFS (HR+/HER2+ subgroup, 5-yr): 91.2% vs 86.8%, HR 0.60
OS (8-yr): HR 0.95 — not significant
IDFS (HR+/HER2+ subgroup, 5-yr): 91.2% vs 86.8%, HR 0.60
OS (8-yr): HR 0.95 — not significant
Adverse events
GI: grade ≥3 diarrhea 39.9% vs 1.6% (without prophylaxis), reduced to ~17% with intensive loperamide prophylaxis; grade ≥3 nausea 2.4%
Other: dose reduction 31.2%; discontinuation 28.1%
Other: dose reduction 31.2%; discontinuation 28.1%
Conclusions
Neratinib significantly improved IDFS at 5 years in HER2+ early BC following trastuzumab-based adjuvant therapy, with the greatest benefit in the HR+/HER2+ subgroup. OS was not significantly improved at 8-year follow-up. Diarrhea management is the primary challenge.
Key Limitations
Key Limitations: Grade ≥3 diarrhea in 40% without prophylaxis is a major barrier — loperamide prophylaxis is mandatory per label but only partially mitigates this. Very high discontinuation rate (28%) limits real-world effectiveness. OS non-significant at 8-year follow-up. The era in which ExteNET enrolled (most patients had not received pertuzumab) means the relevant comparison population has shifted; most current patients have already received dual HER2 blockade (pertuzumab+trastuzumab), reducing the remaining benefit. Most benefit appears restricted to HR+/HER2+ subgroup.
Clinical Context
Neratinib (Nerlynx) received FDA approval in 2017 for extended adjuvant HER2+ early BC after trastuzumab-based therapy. ESMO-MCBS score: 3 (modest IDFS benefit, no OS, high toxicity). Clinical use has been limited by diarrhea burden. In current practice, its role is primarily in HR+/HER2+ patients who completed trastuzumab (without pertuzumab) and are at higher recurrence risk. T-DXd and T-DM1 adjuvant trials have largely overshadowed neratinib in patients with residual disease.
References